Akari Therapeutics Faces Nasdaq Compliance Challenge Amid Volatile Trading

The biotechnology firm Akari Therapeutics finds itself navigating a critical period as it confronts the dual challenge of potential stock exchange delisting and unpredictable market performance. With a key regulatory deadline approaching, investors are watching closely to see if the company can orchestrate a recovery.

Regulatory Countdown Clock Ticking

Akari Therapeutics has been formally notified by Nasdaq regulators that it has fallen out of compliance with listing requirements. The issue stems from the company’s share price remaining below the mandatory $1.00 threshold for 30 consecutive trading sessions.

Management now faces a 180-day window to regain compliance, with a deadline of May 25, 2026. To satisfy exchange rules, the stock must close at or above $1.00 per share for a minimum of ten consecutive business days. The company’s recent performance highlights the magnitude of this challenge—shares have declined 66.59% over the past six months, reducing market capitalization to just $15.94 million. Among potential solutions under consideration is a reverse stock split to mechanically boost the share price.

Unexpected Gains Amid Broader Decline

Despite the concerning backdrop, Akari shares demonstrated notable resilience during recent sessions. On November 28, 2025, the stock advanced 7.6%, building on a 7.62% gain from $0.446 to $0.480 just two days earlier. During that November 28 trading session, the stock fluctuated within a 9.26% range, moving between $0.450 and $0.492.

Should investors sell immediately? Or is it worth buying Akari Therapeutics?

Increased trading volume accompanying these price movements suggests renewed investor interest, though the overall trend remains negative. The equity has still declined 11.59% across the preceding ten trading days. Most recently, shares settled at $0.4864 after closing at $0.4460 previously.

Key developments to monitor:
* Nasdaq compliance requirement: Share price must exceed $1 by May 25, 2026
* Two consecutive trading days with gains exceeding 7% each
* Appointment of new interim CFO with extensive industry background
* Promising preclinical data for cancer treatment PH1

Leadership and Pipeline Developments

Concurrent with its regulatory challenges, Akari is implementing strategic changes. The company has named Kameel D. Farag as interim Chief Financial Officer, bringing over two decades of biopharmaceutical financial leadership to the role. Meanwhile, Chief Executive Officer Abizer Gaslightwala has highlighted encouraging research results for the company’s novel cancer therapeutic PH1. Preclinical studies demonstrated a 74% complete response rate in models of colorectal cancer.

Whether these developments can fundamentally alter the company’s trajectory remains uncertain. The coming weeks will determine if recent price improvements represent temporary volatility or the beginning of a sustained recovery.